TY - JOUR
T1 - Development of target specific agents for bladder cancer
AU - Domingo-Domenech, Josep
AU - Niglio, Scot
AU - Galsky, Matthew D.
N1 - Funding Information:
MD Galsky declares research funding from BMD, Novartis, Genentech and Merck and has been on the advisory board of Genentech, Merck and Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2016/7/3
Y1 - 2016/7/3
N2 - Introduction: There has been a paucity of new therapies developed for the treatment of advanced urothelial cancer due to a convergence of factors including a low prioritization of the disease by industry, therapeutic nihilism, and a limited understanding of the molecular pathogenesis and relevant therapeutic targets. Areas covered: Herein, we review contemporary clinical trials in metastatic urothelial cancer. The review focuses primary on therapeutics directed against somatic genomic alterations, immune checkpoints, and tumor-specific antigen which may serve to selectively deliver cytotoxic payloads (i.e., antibody drug conjugates). Expert commentary: Novel therapeutic approaches have finally established proof of concept in patients with metastatic urothelial cancer. The next few years will witness an expansion of the standard armamentarium and lead to improved outcomes for those suffering with this difficult disease.
AB - Introduction: There has been a paucity of new therapies developed for the treatment of advanced urothelial cancer due to a convergence of factors including a low prioritization of the disease by industry, therapeutic nihilism, and a limited understanding of the molecular pathogenesis and relevant therapeutic targets. Areas covered: Herein, we review contemporary clinical trials in metastatic urothelial cancer. The review focuses primary on therapeutics directed against somatic genomic alterations, immune checkpoints, and tumor-specific antigen which may serve to selectively deliver cytotoxic payloads (i.e., antibody drug conjugates). Expert commentary: Novel therapeutic approaches have finally established proof of concept in patients with metastatic urothelial cancer. The next few years will witness an expansion of the standard armamentarium and lead to improved outcomes for those suffering with this difficult disease.
KW - Head and neck cancer
KW - HNSCC
KW - personalized medicine
KW - precision medicine
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85047469749&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047469749&partnerID=8YFLogxK
U2 - 10.1080/23808993.2016.1208049
DO - 10.1080/23808993.2016.1208049
M3 - Review article
AN - SCOPUS:85047469749
SN - 2380-8993
VL - 1
SP - 361
EP - 368
JO - Expert Review of Precision Medicine and Drug Development
JF - Expert Review of Precision Medicine and Drug Development
IS - 4
ER -